ACHV
Achieve Life Sciences, Inc. Health Care In Vitro & In Vivo Diagnostic Substances Russell 3000
$6.83Close
$363.6MMarket cap
$2.65 – $8.5352-week range
Nov 5, 2026Next report
Highlights
Strengths
- Leading the market RS 88 · stronger than 88% of stocks over 12 months
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
20%
1wk
up 5.2%
price change
1mo
down 15.6%
price change
12-month return
up 30%
market up 11% ·
its own up 27%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
16.9×
price / book
Earnings yield
down 15.9%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 258%
return on equity
Free cash margin
—
-$49.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.9%
$0.40 a day · 2×ATR $6.02
RS
88 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
0.9×
vs 50-day average
Up/down volume
0.78
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 53.5% over the year, from 35m to 53m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 11, 2026
Results reaction
Aug 11, 2026+1% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Net income | -$14.7M | -$33.2M | -$42.4M | -$29.8M | -$39.8M | -$54.6M |
| Earnings per share | -$5.42 | -$4.08 | -$4.00 | -$1.50 | -$1.24 | -$1.25 |
| Free cash flow | -$13.5M | -$29.4M | -$37.6M | -$24.5M | -$29.8M | -$49.5M |
| Cash | $35.9M | $43.0M | $24.8M | $15.5M | $12.8M | $20.9M |
| Shareholders' equity | $37.3M | $28.0M | $8.3M | -$1.4M | $20.9M | $21.5M |
| Shares outstanding | 6.11m | 9.45m | 17.90m | 21.17m | 34.69m | 53.23m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 11, 2026 | Quarterly ↗ | Jun 30, 2026 | 42d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Mar 24, 2026 | Annual ↗ | Dec 31, 2025 | 83d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 11, 2025 | Annual ↗ | Dec 31, 2024 | 70d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 28, 2024 | Annual ↗ | Dec 31, 2023 | 88d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 1, 2026 | Director or officer change ↗ |
| Aug 14, 2026 | Other events ↗ |
| Aug 11, 2026 | Results ↗ |
| Jul 6, 2026 | Charter or bylaws · Shareholder vote ↗ |
| Jun 2, 2026 | Director or officer change ↗ |
| May 12, 2026 | Results · Director or officer change ↗ |
| Apr 16, 2026 | Material agreement · Unregistered share sale · Director or officer change · Regulation FD ↗ |
| Mar 24, 2026 | Results ↗ |
| Nov 6, 2025 | Results ↗ |
| Oct 7, 2025 | Director or officer change ↗ |
| Sep 11, 2025 | Director or officer change ↗ |
| Aug 7, 2025 | Results ↗ |